Nontuberculous Mycobacterium Infection
10
3
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
Hypertonic Saline for MAC
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis
Multi-site Cohort Study for the Development of Personalized Pharmacotherapy in Patients With Tuberculosis (TB)
A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection
WGS of NTM From Sputum of NTM Lung Disease Patients and From Their Environments
Controls for Respiratory Diseases